Clinical traits | Description | Number of patients with reported information |
---|---|---|
Age at diagnosis | Age patient was when diagnosed with disease | 203 |
Survival days | Length of time patient survived (days) since primary diagnosis | 203 |
Binet stage B | Patients diagnosed with Binet Stage B CLL | 15/203 |
Binet stage A | Patients diagnosed with Binet Stage A CLL | 179/203 |
Binet stage C | Patients diagnosed with Binet Stage C CLL | 8/203 |
Male | Â | 116/203 |
Female | Â | 78/203 |
Relapse interval | Length of disease-free interval (days) following primary treatment | 92/203 |
Relapse | Patients with reported relapse event | 92/203 |
Chemotherapy | Patients who received chemotherapy as first treatment | 24/203 |
No treatment | Patients who did not receive any therapy | 9/203 |
IGHV mutated | Patients with Immunoglobulin Heavy Chain mutations | 132/203 |
IGHV unmutated | Patients without Immunoglobulin Heavy Chain mutations | 65/203 |
SF3B1 mutated | Patients with any SNP mutations in the SF3B1 gene | 19/203 |
ATM mutated | Patients with any mutations in the ATM gene | 18/203 |